In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials (PDQ®)

Page Options

  • Print This Page
  • Email This Document
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat
Alemtuzumab Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Mycosis Fungoides/Sezary Syndrome

Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase II, Phase ITreatmentActive18 to 70NHLBICDR0000257524
NHLBI-02-H-0250, NCT00047060

Trial Description

Summary

RATIONALE: Monoclonal antibodies such as alemtuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Allogeneic peripheral stem cell transplantation may be able to replace immune cells that were destroyed by the anticancer therapy. Sometimes the transplanted cells are rejected by the body's normal tissues. Mycophenolate mofetil and cyclosporine may prevent this rejection.

PURPOSE: This phase I/II trial is studying how well giving alemtuzumab together with chemotherapy and donor peripheral stem cell transplantation works in treating patients with advanced mycosis fungoides and/or Sezary syndrome.

Further Study Information

OBJECTIVES:

  • Evaluate the ability of a conditioning regimen comprising alemtuzumab and fludarabine with or without cyclophosphamide to produce at least 80% sustained engraftment in patients with advanced mycosis fungoides/Sezary syndrome.
  • Evaluate allogeneic graft-versus-tumor effects in mycosis fungoides/Sezary syndrome patients treated with a nonmyeloablative conditioning regimen followed by HLA-matched allogeneic peripheral blood stem cell transplantation.
  • Determine the safety and toxicity of this regimen in these patients.
  • Determine tumor response, disease-free survival, and overall survival of patients treated with this regimen.
  • Determine the rate and extent of lymphocyte subset reconstitution in patients treated with this regimen.
  • Determine transplant-related morbidity, including rates of acute and chronic graft-versus-host disease and infectious complications, and mortality in patients treated with this regimen.

OUTLINE: Patients receive 1 of 2 nonmyeloablative conditioning regimens, depending on engraftment efficacy in prior patients.

  • Regimen A: Patients receive alemtuzumab IV over 2 hours on days -28, -27, -26, -24, -22, -19, -17, and -15 and fludarabine IV over 30 minutes on days -5 to -1.
  • Regimen B: Patients receive alemtuzumab and fludarabine as in regimen A plus cyclophosphamide IV over 1 hour on days -7 and -6.

Patients also receive graft-versus-host disease prophylaxis comprising oral cyclosporine twice a day beginning on day -4 and continuing until day 100.

Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.

Donor T cell and myeloid chimerism will be evaluated and will guide decisions regarding donor lymphocyte infusions.

Patients are followed every 2 months for 6 months, every 3 months for 1.5 years, and then every 6 months for 3 years.

PROJECTED ACCRUAL: A total of 9-58 patients will be accrued for this study.

Eligibility Criteria

DISEASE CHARACTERISTICS:

  • One of the following diagnoses:
  • Histologically confirmed mycosis fungoides (MF)
  • Stage IIB, III, IVA, or IVB
  • Progressive disease after at least 1 treatment regimen
  • Sezary syndrome (SS)
  • Clinically or radiographically evaluable disease
  • Anticipated median survival of less than 5 years or debilitation as result of disease
  • Less than 25% of liver involved with metastatic tumor by CT scan
  • No CNS metastases by MRI
  • 6/6 HLA-matched family donor available

PATIENT CHARACTERISTICS:

Age

  • 18 to 70

Performance status

  • ECOG 0-1

Life expectancy

  • See Disease Characteristics
  • At least 3 months

Hematopoietic

  • Not specified

Hepatic

  • See Disease Characteristics
  • Bilirubin no greater than 4 mg/dL
  • Transaminases no greater than 5 times upper limit of normal

Renal

  • Creatinine no greater than 2 mg/dL

Cardiovascular

  • LVEF at least 40%

Pulmonary

  • DLCO at least 60% of predicted

Other

  • HIV negative
  • Not pregnant or nursing
  • Negative pregnancy test
  • No major organ dysfunction or failure or major anticipated illness that would preclude transplantation
  • No psychiatric disorder or mental deficiency that would preclude study
  • No other malignancy within the past 5 years except basal cell or squamous cell skin cancer

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Not specified

Chemotherapy

  • Not specified

Endocrine therapy

  • Not specified

Radiotherapy

  • Not specified

Surgery

  • Not specified

Other

  • At least 30 days since prior therapy for MF or SS

Trial Contact Information

Trial Lead Organizations/Sponsors

National Heart, Lung, and Blood Institute

Ramaprasad SrinivasanStudy Chair

Trial Sites

U.S.A.
Maryland
  Bethesda
 NIH - Warren Grant Magnuson Clinical Center
 Patient Recruitment Ph: 800-411-1222

See All Trial Sites

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00047060
ClinicalTrials.gov processed this data on October 17, 2013

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.

Back to TopBack to Top